Clinical Trials Logo

Pharmacodynamics clinical trials

View clinical trials related to Pharmacodynamics.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04911270 Active, not recruiting - Pharmacokinetics Clinical Trials

Clinical Decision Support Tool for Vancomycin Dosing in Children

Start date: May 9, 2022
Phase: N/A
Study type: Interventional

This study will evaluate the pharmacokinetic and pharmacodynamic dosing properties of intravenous vancomycin in pediatric patients using a novel computer decision support (CDS) tool called Lyv. Dosing will be individualized based on AUC24/MIC. The results will be compared to matched historical controls.

NCT ID: NCT04250038 Active, not recruiting - Pharmacokinetics Clinical Trials

Association of Cefepime Trough Levels With Clinical Efficacy and Neurotoxicity in Patients With Febrile Neutropenia

Start date: August 1, 2019
Phase:
Study type: Observational

In this prospective monocenter observational study, the objective was to determine a safe and effective therapeutic window for cefepime in patients with neutropenic fever.

NCT ID: NCT04131218 Active, not recruiting - Pharmacokinetics Clinical Trials

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

Start date: July 16, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese patients undergoing bariatric surgery.

NCT ID: NCT01226316 Active, not recruiting - Ovarian Cancer Clinical Trials

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Start date: December 1, 2010
Phase: Phase 1
Study type: Interventional

This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug). This study will also investigate anti-tumour activity of AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid cancers bearing either AKT1 / PIK3CA or PTEN mutation.